-
XM1.1 (A,B,C): VOR latency during VHIT
Time frame: 4 years post-implantation up to 5 years post-enrollment
Vestibulo-ocular reflex (VOR) latency is measured in milliseconds for responses during video head impulse testing (described in 2.EM1.1) with study device providing three different modes of prosthetic vestibular nerve stimulation (A=motion-modulated/ treatment-mode stimulation, B=constant/placebo-mode stimulation, or C=no stimulation). Results are reported as a three-element vector of latencies relative to preoperative baseline (latency during mode A stimulation at 4 yr post-implantation, latency during mode B stimulation at 4 yr post-implantation, latency during mode C stimulation at 4 yr post-implantation). Latencies range from 0-1000 ms, smaller values meaning better outcome.
-
XM1.2 (A,B,C): saccade latency during VHIT
Time frame: 4 years post-implantation up to 5 years post-enrollment
Saccade (VOR) latency is measured in milliseconds for responses during video head impulse testing (described in 2.EM1.1) with study device providing three different modes of prosthetic vestibular nerve stimulation (A=motion-modulated/ treatment-mode stimulation, B=constant/placebo-mode stimulation, or C=no stimulation). Results are reported as a three-element vector of latencies relative to preoperative baseline (latency during mode A stimulation at 4 yr post-implantation, latency during mode B stimulation at 4 yr post-implantation, latency during mode C stimulation at 4 yr post-implantation). Latencies range from 0-1000 ms, smaller values meaning better outcome.
-
XM2.1 (A,B,C): VOR gain-time constant product during whole-body yaw rotary chair velocity step rotations toward the implanted ear
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant sits on a chair atop an Earth-vertical-axis rotating motor in darkness, wearing goggles that contain a camera to monitor eye rotation. The motor rotates at 240 deg/s for 1 min toward the implanted side. Slow phase nystagmus velocity is measured. Vestibulo-ocular reflex gain-time constant product GainTc is computed by multiplying gain (ratio of peak slow phase eye speed to peak chair speed) by time constant (duration after which the eye movement speed has decayed to 37% of its initial peak). GainTc ranges from 0 to 60 sec. Higher values mean better outcomes. It is measured and reported for responses during rotating chair testing with study device providing three different modes of prosthetic vestibular nerve stimulation (A=motion-modulated/ treatment-mode stimulation, B=constant/placebo-mode stimulation, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM2.2 (A,B,C): VOR frequency response during whole-body yaw rotary chair sinusoidal rotations
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant sits on a chair atop an Earth-vertical-axis rotating motor in darkness, wearing goggles that contain a camera to monitor eye rotation. The motor rotates sinusoidally at 100 deg/s peak velocity and frequency 0.05/0.1/0.2/0.5/1 Hz. Slow phase nystagmus velocity is measured. The frequency response is a 5-element vector (one per stimulus frequency) of complex numbers, each comprising a unitless gain (eye velocity amplitude divided by chair velocity amplitude) and phase equal to 360 deg times ratio (time from peak eye velocity to peak head velocity)/(period of sinusoidal stimulus). Each gain ranges from 0 to 1; higher values mean better outcome. Each phase ranges from -180 to 180; values nearer zero mean better outcome. Frequency response is reported as a 3x5 matrix of values relative to preoperative baseline for testing with study device providing three modes of vestibular nerve stimulation: A=motion-modulated, B=constant-rate, C=off.
-
XM3.1: electrically-evoked vestibulo-ocular reflex (eeVOR) response peak magnitude for largest response on each electrode
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant sits on a motionless chair atop in darkness, wearing goggles that contain a camera to monitor eye rotation. The vestibular implant's stimulator delivers a series of electrical pulse trains to the inner via each electrode, one at a time. Slow phase nystagmus velocity is measured using the camera. For each canal, the largest measured nystagmus velocity is recorded. Velocities are reported as a 3-valued vector (the highest peak velocity measured for each of the three semicircular canals in the implanted ear), with values ranging from 0-300 deg/s and higher values meaning better outcomes.
-
XM3.2: electrically-evoked vestibulo-ocular reflex (eeVOR) response 3D misalignment for largest response on each electrode
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant sits on a motionless chair atop in darkness, wearing goggles that contain a camera to monitor eye rotation. The vestibular implant's stimulator delivers a series of electrical pulse trains to the inner via each electrode in each semicircular canal, one at a time. Slow phase nystagmus velocity is measured using the camera. For each canal, 3-dimensional (3D) misalignment (the angle in degrees between the 3D axis of peak velocity eye rotation and the 3D axis of the targeted semicircular canal) is measured for the peak nystagmus elicited by each electrode and stimulus intensity. 3D misalignment is reported as a 3-valued vector (the misalignment angles measured for each of the three semicircular canals in the implanted ear, using the electrodes and stimulus intensities that yield the largest responses approximately aligned with the target canal's axis), with values ranging from 0-180 deg and smaller values meaning better outcomes.
-
XM4 (A,B,C): time to failure on Modified Romberg Test with Eyes Closed on Foam
Time frame: 4 years post-implantation up to 5 years post-enrollment
The Modified Romberg Test with Eyes Closed on Foam involves having the participant stand for as long as possible on a foam pad with feet together, arms crossed, and eyes closed. Time to failure (i.e., moving out of position or opening the eyes) is measured for a maximum of 30 seconds for each of two attempts, and the longer of two measured durations is reported in seconds, with higher values meaning better outcomes. Values are measured with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/ treatment-mode, B=constant/placebo-mode, or C=no stimulation) and reported as a 3-valued vector.
-
XM5.1 (A,B,C): slope of change in treadmill dynamic visual acuity with increasing walking speed (LogMAR/mph)
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant's visual acuity is measured while standing still and then while walking on a treadmill at 0.5, 1, 1.5, 2, 2.5 and 3 miles per hour (mph). The slope with which visual acuity (in logarithm base 10 of the minimum angle resolved, logMAR) worsens as treadmill speed increases (in mph) is measured from a line fit to the data and reported in units of (logMAR/mph), with values ranging from 0 to -1 and less negative numbers meaning better outcome. The test is repeated with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/ treatment-mode, B=constant/placebo-mode, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM5.2 (A,B,C): maximum treadmill velocity achieved during (mph)
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant's visual acuity is measured while standing still and then while walking on a treadmill at 0.5, 1, 1.5, 2, 2.5 and 3 miles per hour (mph). The highest treadmill speed the participant tolerates is recorded in mph, with higher speeds meaning better outcome. The test is repeated with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/treatment-mode, B=constant/placebo-mode, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM6.1 (A,B,C): gait speed when walking in well-light hall
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant walks in a well-lit hall while gait speed is measured in m/s. Speeds range from 0-2 m/s, with higher values meaning better outcome. The test is repeated with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/treatment-mode, B=constant/placebo-mode, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM6.2 (A,B,C): gait speed when walking in dim light
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant walks in dim light while gait speed is measured in m/s. Speeds range from 0-2 m/s, with higher values meaning better outcome. The test is repeated with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/treatment-mode, B=constant/placebo-mode, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM7.1 (A,B,C): TUG when walking in well-light hall
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant performs the Timed Up and Go (TUG) test, which comprises rising from a chair, walking to and around a pylon, then returning to the chair and sitting, in a well-lit hall. Time to complete the TUG ranges over ~5-30 seconds, with lower values meaning better outcome. The test is repeated with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/treatment-mode, B=constant/placebo-mode, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM7.2 (A,B,C): TUG when walking in dim light
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant performs the Timed Up and Go (TUG) test, which comprises rising from a chair, walking to and around a pylon, then returning to the chair and sitting, in dim light. Time to complete the TUG ranges over ~5-30 seconds, with lower values meaning better outcome. The test is repeated with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/treatment-mode, B=constant/placebo-mode, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM8.1 (A,B,C): gait speed when walking during dual task/cognitive distraction (Serial 7s downward counting)
Time frame: 4 years post-implantation up to 5 years post-enrollment
While counting downward in increments of -7 (from a number randomly selected between 91 and 109 by the examiner), a participant walks in a well-lit hall and gait speed is measured in m/s. Speeds range from 0-2 m/s, with higher values meaning better outcome. The test is repeated with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/treatment-mode, B=constant/placebo-mode, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM8.2 (A,B,C): TUG during dual task/cognitive distraction (Serial 7s)
Time frame: 4 years post-implantation up to 5 years post-enrollment
While counting downward in increments of -7 (from a number randomly selected between 91 and 109 by the examiner), a participant performs the Timed Up and Go (TUG) test, which comprises rising from a chair, walking to and around a pylon, then returning to the chair and sitting, in dim light. Time to complete the TUG ranges over ~5-30 seconds, with lower values meaning better outcome. The test is repeated with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/treatment-mode, B=constant/placebo-mode, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM9 (A,B,C): Serial 7s downward counting while standing with eyes open
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant counts downward for 20 seconds in increments of -7 (from a number randomly selected between 91 and 109 by the examiner) while standing with eyes open. The number of increments correctly subtracted is counted, with higher number of increments meaning better performance. The test is repeated with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/treatment-mode, B=constant/placebo-mode, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM10.1 (A,B,C): time to complete the Trail Making Test Part B (TMT)
Time frame: 4 years post-implantation up to 5 years post-enrollment
A participant performs the Trail Making Test Part B (TMT), using a pen to connect a set of 25 pre-drawn and numbered circles on a sheet of paper as quickly as possible while being accurate. The time in seconds required to complete the test is recorded, with shorter time meaning better performance. The test is repeated with the study device providing three different modes of prosthetic stimulation (A=motion-modulated/treatment-mode, B=constant/placebo-mode, or C=no stimulation). Results are reported as a 3-valued vector.
-
XM10.2 (A,B,C): performance on the Triangle Completion Test (TCT)
Time frame: 4 years post-implantation up to 5 years post-enrollment
After a practice trial with eyes open, a participant performs the Triangle Completion Test (TCT). The blindfolded participant is assisted while walking slowly along 2 segments of a pre-drawn 92.5 × 185.5 × 212 cm, 30°-60°-90° triangular path and instructed to complete the final segment independently, ending at his/her best estimate of the starting point. The participant walks counterclockwise for two triangles and then clockwise for two. End point is marked midway between each foot's largest toe. Distance (in cm, range ~0-100, smaller better) from end point to starting point and angle (absolute value, range 0-180 deg, smaller better) between the participant's path and the correct path are averaged over four trials. The test is repeated with the study device providing three modes of prosthetic stimulation: A (motion-modulated), B (constant rate) and C (off). Results are reported as a 3 by 2-valued matrix.
-
XM11: electrode impedance
Time frame: 4 years post-implantation up to 5 years post-enrollment
Electrical impedances are measured using 26.67 microsecond/phase biphasic current pulses at 302.4 cu (clinical units) of current for each of the 9 stimulating electrodes and reported as a 9-valued vector. Values range from 0 to 25 kiloohm (kΩ). Values of <2 kΩ, abnormally low and values >15 kΩ are abnormally high, values in the range 2-15 kΩ are normal, and values closer to normal range mean better outcome. Impedances for the 9 electrodes are reported as a 9-valued vector.
-
XM12: electrode location distance, as determined by post-implantation computed tomography (CT) imaging
Time frame: 4 years post-implantation up to 5 years post-enrollment
For each canal, the distance between the center of crista ampullaris and the nearest stimulating electrode is measured on a post-implantation computed tomography (CT) scan in mm, with values ranging from 0-5 mm and smaller values meaning better outcome. Best-electrode distances for the 3 canals are reported as a 3-valued vector.
-
XM13: vestibular evoked compound action potential (veCAP)24 amplitude
Time frame: 4 years post-implantation up to 5 years post-enrollment
Peak vestibular-evoked compound action potential (veCAP) amplitude is measured for each implanted electrode and reported for the 9 implanted electrodes, with range 0-1000 microvolts and higher values meaning better outcome, as a 9-valued vector.
-
XM14.1: scalp thickness over the implant, measured on post-operative CT imaging
Time frame: 4 years post-implantation up to 5 years post-enrollment
Scalp thickness over the implant is measured in mm using a post-operative CT scan performed 3 weeks after implantation.
-
XM14.2: inductively-measured intercoil distance between implant antenna coil and external processor antenna coil
Time frame: 4 years post-implantation up to 5 years post-enrollment
Inductively-measured intercoil distance between implant antenna coil and external processor antenna coil is measured in mm 3 weeks after implantation and 4 years post-implantation, and the change between those two values is reported in mm, with numbers less than (initial thickness minus 3 mm) meaning better outcome.
-
XM15.1: Bilateral Vestibulopathy Questionnaire score (BVQ)
Time frame: 4 years post-implantation up to 5 years post-enrollment
The Bilateral Vestibulopathy Questionnaire English version (BVQ) is a 24-question survey intended to quantify patient-reported disease burden due to bilateral vestibular hypofunction. Each question is answered on a 6-item Likert scale, with scores for positively-worded questions reversed before scoring. After averaging scores within each of 4 construct subsets, the 4 construct values are added to yield overall BVQ score, ranging from 4 to 24. Higher score means worse outcome.
-
XM15.2: Number of Audio/video recording of structured interviews
Time frame: 4 years post-implantation up to 5 years post-enrollment
Audio and video recording of a participant's responses to a structure set of questions regarding symptoms of bilateral vestibular hypofunction will be made preoperatively and at 4 years postoperatively. Responses are free-format and not quantified. The number of participants who complete video/imaging will be reported.
-
XM16: Vestibular Activities of Daily Living score (VADL)
Time frame: 4 years post-implantation up to 5 years post-enrollment
Vestibular Activities of Daily Living (VADL) is a survey designed to quantify self-rated disability due to vestibular dysfunction. Scores range from 1 (least disabled, best outcome) to 10 (worst outcome) points.
-
XM17 (A,B,C): Oscillopsia Visual Analog Scale score (oVAS)
Time frame: 4 years post-implantation up to 5 years post-enrollment
The Oscillopsia Visual Analog Scale (oVAS) is a 43-question survey designed to quantify self-rated oscillopsia. Each item is answered on a 6-point Likert scale (integer scores of 0 to 5, with the score X for each negatively phrase questions transformed to 5-X before summation across all questions). Total score ranges from 0 (least oscillopsia, best outcome) to 215 (worst outcome) points.
-
XM18: Activities-specific Balance Confidence Scale score (ABC)
Time frame: 4 years post-implantation up to 5 years post-enrollment
The Activities-specific Balance Confidence Scale (ABC) is a 16-question survey designed to quantify self-rated confidence performing daily activities that require balance. Each item is answered on an 11-item Likert scale (from 0 to 100% confidence, in 10% increments). Total score is the average of the 16 responses and ranges from 0 (least confident, worst outcome) to 100% (most confident, best outcome).
-
XM19.1: Vertigo Symptom Scale score (VSS)
Time frame: 4 years post-implantation up to 5 years post-enrollment
The vertigo-balance subscale score of the Vertigo Symptom Scale is a 15-item survey designed to quantify self-rated vertigo symptom severity. Each item is answered on a 5-item Likert scale (from 0 to 4, higher meaning more frequent/worse symptoms). Total score is the sum of the 15 responses and ranges from 0 (least severe/frequent, best outcome) to 75 (worst outcome).
-
XM19.2: Vertigo Visual Analogue Scale score (VAS)
Time frame: 4 years post-implantation up to 5 years post-enrollment
The Vertigo Visual Analogue Scale is a 9-item visual analogue scale designed to assess the intensity of vertigo symptoms for patients in different daily situations that typically induce visual vertigo. Each item is answered on a visual analogue scale by drawing a vertical line on a 10 cm line between two anchors marked 0 and 10 (with zero (0) representing no dizziness and ten (10) representing most dizziness). Total score is the sum of the 9 responses, divided by the number of answered items, and multiplied by 10. (ranges from 0 (least severe, best outcome) to 100 (most severe, worst outcome).
-
XM20.1: Health Utilities Index Mark 3 (HUI)
Time frame: 4 years post-implantation up to 5 years post-enrollment
The Health Utilities Index Mark 3 is an instrument designed to measure health status and health-related quality of life. HUI Mark 3 provides a utility score ranging from 0 (worst outcome) to 1 (best outcome).
-
XM20.2: EuroQol 5 Dimension (EQ-5D)
Time frame: 4 years post-implantation up to 5 years post-enrollment
The EuroQOL EQ5D is a 5-dimension (mobility, self-care, usual activities, pain/discomfort, anxiety depression) instrument developed to evaluate health-related quality of life. Each of the five dimensions includes five levels of severity going from 1-5 (no problems (1), slight problems (2), moderate problems (3), severe problems (4), unable to/extreme problems (5)). Scores for each dimension are combined to obtain a total score in the form of a 5 digit code (Greater number of higher scores means worse outcome.)
-
XM21: Tinnitus Handicap Inventory (THI)
Time frame: 4 years post-implantation up to 5 years post-enrollment
The Tinnitus Handicap Inventory (THI) survey is set of questions designed to quantify self-perceived handicap due to tinnitus. THI score ranges from 0-100. Higher scores mean worse outcome.
-
XM22: Autophony Index (AI)
Time frame: 4 years post-implantation up to 5 years post-enrollment
The Autophony Index (AI) survey is set of questions designed to quantify self-perceived autophony (hearing one's voice or other internally-generated body sounds). AI score ranges from 0-104. Higher scores mean worse outcomes.
-
XM23.1: OTOSCOPE genetic testing panel (or equivalent panel from another Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory, such as Invitae Corpl) for participants who agree to genetic testing
Time frame: Preoperative baseline
For participants with a history of nonototoxic bilateral vestibular hypofunction who agree to clinical genetic testing, a University of Iowa Molecular Otology Research Laboratory OtoSCOPE® Genetic Hearing Loss Testing v9 test will be performed on a buccal swab to determine the presence or absence of an identifiably inner ear gene abnormality, and the deidentified result will be reported.
-
XM23.2: Presence or absence of Mitochondrially Encoded 12S RRNA (MTRNR1) gene abnormality as assessed by genetic test panel (or equivalent) for participants with known ototoxic exposure who agree to genetic testing
Time frame: Preoperative baseline
For participants with a history of ototoxic bilateral vestibular hypofunction who agree to clinical genetic testing, an MTRNR1 genetic testing panel screen will be completed to determine the presence or absence of an MTRNR1 gene abnormality, and the deidentified result will be reported.
-
XM23.3: RFC1 presence or absence of an MTRNR1 gene abnormality as assessed by Ataxia/CANVAS genetic testing panel (or equivalent) for participants suspected to have CANVAS or demonstrate potential CANVAS related symptoms
Time frame: Preoperative baseline
For participants with a history of ototoxic bilateral vestibular hypofunction who agree to clinical genetic testing, an MTRNR1 genetic testing panel screen will be completed to determine the presence or absence of an MTRNR1 gene abnormality, and the deidentified result will be reported.
-
XM24.1: Number of intraoperative video recordings of electrode implantation
Time frame: Intraoperatively
Deidentified video of the implantation surgery will be recorded intraoperatively. The number of participants who complete intraoperative recording will be reported.
-
XM24.2: Number of post-implantation temporal bone CT imagings
Time frame: 3 weeks post-implantation
Deidentified images for a post-implantation temporal bone computed tomography (CT) scan will be recorded 3 weeks post-implantation. The number of participants who complete imaging will be reported.
-
XM25: Study visit duration (days) by activity/test/assessment
Time frame: 4 years post-implantation up to 3 years post-enrollment
Explore ways to improve efficiency of procedures for performance assessment and stimulus parameter adjustment by measuring change in study visit duration by activity/test/assessment.
-
XM26: Number of audio/video recording of participants' descriptions of motion percepts during eeVOR testing
Time frame: 4 years post-implantation up to 3 years post-enrollment
Deidentified audio/video of the of participants' descriptions of motion percepts during eeVOR testing. The number of participants who complete video/recording will be reported.